Lysergic acid diethylamide precautions

Jump to: navigation, search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

List of precautions

General

Augmentation systemic absorption

HPA axis suppression

Pediatric patients



General

Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Return to top

Augmentation systemic absorption

Conditions which augment systemic absorption include use over large surface areas, prolonged use, and use under occlusive dressings. Use of more than one corticosteriod-containing product at the same time may increase total systemic glucocorticoid exposure. Patients applying LOTRISONE® Cream or Lotion to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, morning plasma cortisol, and urinary-free cortisol tests. Return to top

HPA axis suppression

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. Return to top

Pediatric patients

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Return to top



Adapted from the FDA Package Insert.


Linked-in.jpg